Background: The most frequent histological types of rhabdomyosarcoma (RMS) in children are embryonal (ERMS) and alveolar (ARMS) tumours. The majority of ARMS are characterized by the presence of PAX3/7-FOXO1 gene fusion and have a worse prognosis than fusion gene-negative ARMS. However, identification of PAX3/7-FOXO1 fusion status is challenging when using formalin-fixed, paraffin-embedded (FFPE) material. Microarray analyses revealed that high expression of several genes is associated with PAX3/7-FOXO1 fusion status. Therefore, we investigated if immunohistochemical approach may detect surrogate marker genes as indicators of fusion gene-positive RMS.
Methods: Forty five RMS patients were included in the analysis and immunohistochemistry was applied to FFPE tissues collected at diagnosis. Protein expression of OLIG2, a novel marker in RMS, was investigated using antibody EP112 (Cell Marque). In addition already known two markers were also analyzed: TFAP2B using rabbit anti-TFAP2β antibody (Santa Cruz Biotechnology) and ALK using anti-ALK antibody clone D5F3 #3633 (Cell Signalling). Fluorescence in situ hybridization (FISH) was performed on FFPE sections with FOXO1/PAX3 and/or FOXO1/PAX7 probes (Dual Colour Single Fusion Probe, Zytovision).
Results: Our analysis revealed that all three immunohistochemical markers are associated with the presence of PAX3/7-FOXO1 fusion: TFAP2B (p < 0.00001), OLIG2 (p = 0.0001) and ALK (p = 0.0007). Four ARMS had negative PAX3/7-FOXO1 status and none of them displayed positive reaction with the analysed markers. Positive reaction with OLIG2 (6 tumours) was always associated with the presence of PAX3/7-FOXO1 rearrangement. Two additional OLIG2 positive cases showed inconclusive FISH results, but were positive for TFAP2B and ALK, what suggests that these tumours expressed fusion positive signature.
Conclusion: Our results indicate that TFAP2B, ALK and a novel marker OLIG2 may serve as surrogate markers for PAX3/7-FOXO1 status what is especially beneficial in cases where poor quality tumour tissue is not suitable for reliable genetic analyses or shows inconclusive result.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731563 | PMC |
| http://dx.doi.org/10.1186/s13000-019-0883-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rhabdomyosarcoma in children and young adults.
Virchows Arch
December 2024
Department of Pathology and Laboratory Medicine, Indiana University, 350 W 11st St, Indianapolis, IN, 46202, USA.
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in childhood, accounting for 3% of all pediatric malignancies and 50% of all pediatric soft tissue sarcomas. In adolescents and young adults (AYA) however, RMS comprises only 6.5% of all soft tissue sarcomas.
View Article and Find Full Text PDFTRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma.
Exp Hematol Oncol
April 2024
Childhood Cancer and Blood Disorders, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Article Synopsis
- Rhabdomyosarcoma (RMS) treatment has improved, but high-risk patients still struggle with poor survival rates due to issues like PAX3/7-FOXO1 fusion proteins that cause metastasis and resistance to therapy.
- This study focused on TRIB3, a regulator of FOXO1, finding that higher TRIB3 expression in RMS tumors correlates with the fusion protein's presence and contributes to cell proliferation.
- Genetic inhibition of TRIB3 not only reduced PAX3-FOXO1 levels and affected signaling pathways but also delayed tumor growth and improved survival rates in vivo, indicating TRIB3 could be a promising therapeutic target for aggressive RMS.
Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
JCO Precis Oncol
October 2022
Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
Article Synopsis
- Rhabdomyosarcomas (RMS) are rare cancers in children and young adults, and the study seeks to explore the use of circulating tumor DNA (ctDNA) as a biomarker for disease monitoring and treatment response because suitable markers are currently lacking.
- The researchers used RMS mouse models and tested different techniques like PCR and ddPCR to detect ctDNA in blood samples, identifying mutations and alterations related to the disease.
- They found ctDNA in 14 out of 18 pretreatment plasma samples from RMS patients, with higher levels indicating more severe disease, suggesting that ctDNA can be a useful and less invasive tool for tracking RMS and evaluating treatment efficacy.
Diagnostic Immunohistochemistry of Soft Tissue and Bone Tumors: An Update on Biomarkers That Correlate with Molecular Alterations.
Diagnostics (Basel)
April 2021
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
The diagnosis of benign and malignant soft tissue and bone neoplasms is a challenging area of surgical pathology, due to the large number, rarity, and histologic diversity of tumor types. In recent years, diagnosis and classification has been aided substantially by our growing understanding of recurrent molecular alterations in these neoplasms. Concurrently, the role of diagnostic immunohistochemistry has also expanded, with the development of numerous biomarkers based on underlying molecular events.
View Article and Find Full Text PDFOLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Diagn Pathol
September 2019
Department of Pathology, The Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland.
Background: The most frequent histological types of rhabdomyosarcoma (RMS) in children are embryonal (ERMS) and alveolar (ARMS) tumours. The majority of ARMS are characterized by the presence of PAX3/7-FOXO1 gene fusion and have a worse prognosis than fusion gene-negative ARMS. However, identification of PAX3/7-FOXO1 fusion status is challenging when using formalin-fixed, paraffin-embedded (FFPE) material.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!